Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05867381

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
112 (estimated)
Sponsor
University of Southern California · Academic / Other
Sex
All
Age
65 Years – 84 Years
Healthy volunteers
Not accepted

Summary

This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.

Detailed description

This double-blind, randomized, crossover trial will recruit 112 adults with ischemic heart disease history and will investigate potential benefits of indoor high efficiency particulate air (HEPA) filtration on ameliorating the progression of atherothrombosis. Participants will be contacted and recruited to the study based on inclusion and exclusion criteria. After consenting, participants will go through a total of 21-month study period comprised of true HEPA filtration and sham filtration, each of 9-month in duration, and a 3-month wash-out period. After 3-month wash-out period, participants will be switched to the other arm of the intervention. During the trial, project specialists will complete a series of home visits before, in the middle, and after each intervention session to set up air purifiers and indoor and outdoor air pollution monitors, as well as conduct interview to collect questionnaire data, measure vascular function, blood pressure, and collect biospecimens. Participants will self-monitor their daily blood pressure through out the intervention periods. In aim 1, researchers will assess the effect of a 9-month residential HEPA intervention on atherothrombosis progression in 112 participants. In aim 2, the researchers will examine the association between reduction in indoor PM2.5 exposure brought by the intervention and the changes in atherothrombosis progression indicators adjusting for outdoor PM2.5 exposure. In aim 3, researchers will examine atherothrombosis responses (both levels and slopes of change) to the HEPA intervention within four subgroups of participants: 1) non-Hispanics, 2) Hispanics, 3) females, and 4) males.

Conditions

Interventions

TypeNameDescription
DEVICEHEPA filtrationHEPA filters with the capacity to reduce PM2.5 levels
DEVICESham filtrationSham filtration use the same appearance of air purifier but with HEPA filter removed.

Timeline

Start date
2023-07-11
Primary completion
2027-06-30
Completion
2027-06-30
First posted
2023-05-22
Last updated
2025-08-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05867381. Inclusion in this directory is not an endorsement.